Skip to main content
Stanley Appel, MD, Neurology, Houston, TX, Houston Methodist Hospital

StanleyHAppelMD

Neurology • Houston, TX

Peggy & Gary Edwards Distinguished Endowed Chair, Stanley H. Appel Department of Neurology Professor of Neurology, Institute for Academic Medicine Full Member, Research Institute Director, Neurological Institute Houston Methodist Weill Cornell Medical College

Join to view full profile

Dr. Appel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Appel's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Neurology, 1965 - 1966
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1961 - 1962
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1960 - 1961
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 1960

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1977 - 2025
  • NC State Medical License
    NC State Medical License 1967 - 1982
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Investigator Alumnus Howard Hughes Medical Institute, 1976
  • Elected Member The American Society for Clinical Investigation, 1969
  • Top MD Consumers Checkbook
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy Trial
    Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023
  • Alzheimer’s Diagnoses Expected to Reach Nearly 13 Million by 2050, Says New Report
    Alzheimer’s Diagnoses Expected to Reach Nearly 13 Million by 2050, Says New ReportMarch 17th, 2023
  • Eledon’s Antibody, Tegoprubart, Shows Promise in ALS Phase 2 Trial
    Eledon’s Antibody, Tegoprubart, Shows Promise in ALS Phase 2 TrialJune 2nd, 2022
  • Join now to see all

Grant Support

  • Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To InNational Center For Research Resources2011
  • Using CD4+ T Cells As A Candidate Therapy To Slow Disease Progression In ALSNational Institute Of Neurological Disorders And Stroke2010–2011
  • Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To INDNational Center For Research Resources2010
  • The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2005–2007
  • The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2004
  • Selective Vulnerability Of Sporadic Neurodegenerative DiseaseNational Institute On Aging1997–2000
  • Alzheimers Disease Research CenterNational Institute On Aging1994–2000
  • ALS IGG Effects On Motorneuron UntrastructureFogarty International Center1996–1998
  • Selective Neuronal Vulnerability In Sporadic ALSNational Institute Of Neurological Disorders And Stroke1994–1997
  • Alzheimer'S Disease Research CenterNational Institute On Aging1989–1993
  • NeurosciencesNational Institute Of Neurological Disorders And Stroke1988
  • Neurosciences Training ProgramNational Institute Of Neurological Disorders And Stroke1985–1987

Hospital Affiliations

Dr. Stanley Appel, Dr. Stanley Appel, MD, Dr. S Appel, Dr. Stanley H Appel